MES Shares Mesoblast Limited
ASX
$2.40
—
Prices as of close 2026-10-27
Last in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Commercial Ryoncil growth and late-stage catalysts support substantial re-rating potential.
Future value: $4.27 (+77.90%) · 6-12 months
Signal breakdown
- ▸Commercial launch momentum and late-stage clinical catalysts.
Is MES a buy right now?
Our screen: BUY (score 2) — Commercial Ryoncil growth and late-stage catalysts support substantial re-rating potential.
Computed from end-of-day data; not personal advice.
Related Biotech picks
CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.
Browse: all ASX stocks · Biotech picks · today's movers
General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.